What is Anika Therapeutics Price-to-Free-Cash-Flow?
As of today (2024-04-29), Anika Therapeutics's share price is $26.06.
Anika Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49. Hence, Anika Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Anika Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Anika Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 319.36. The lowest was 10.86. And the median was 24.28.
ANIK's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.635 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 13 years, Anika Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 160.40% per year. The lowest was -52.40% per year. And the median was 6.60% per year.
Anika Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Anika Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anika Therapeutics's Price-to-Free-Cash-Flow
For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Price-to-Free-Cash-Flow falls into.
Anika Therapeutics's Share Price of today is $26.06. Anika Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Anika Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Anika Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Anika Therapeutics (Anika Therapeutics) Business Description
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANIK has been successfully added to your 